Novel RNA Markers in Prostate Cancer: Functional Considerations and Clinical Translation

Table 2

MiRNA-based biomarker studies in prostate cancer.

Trial title	Objectives	Study type	Source	Trial number
Micro-RNA Expression Profiles in High Risk Prostate Cancer	Correlation of miRNA expression with prostate cancer outcome	Observational retrospective	Radical prostatectomy	NCT01220427^a
Blood and Tissue Samples From Patients with Locally Recurrent or Metastatic Prostate Cancer	Sequencing of genomic tumor DNA, genotyping, gene expression, and miRNA/noncoding RNA	Observational prospective	Blood, soft tissue or bone metastases	NCT01050504^a
MicroRNA in Prostate Cancer Progression: Genetic Variation, Genotype-Phenotype Correlation, and Circulating Biomarker	MiRNAs as predictors of progression	Biomarker screening	Tumor versus normal tissue, plasma	MD Anderson Cancer Center^b
Abiraterone Acetate in Treating Patients with Metastatic Hormone-Resistant Prostate Cancer	MiRNA expression in tumor metastases as biomarker for sensitivity and resistance; correlation of miRNA with response and progression	Interventional, Phase II clinical trial	Blood (biopsy)	NCT01503229^a
Bicalutamide and Goserelin or Leuprolide Acetate w/wo Cixutumumab in Patients with Newly Diagnosed Metastatic Prostate Cancer	Correlation of miRNA expression and CTC count	Interventional, Phase II clinical trial	Serum	NCT01120236^a

^ahttp://clinicaltrials.gov.
^bhttp://www.mdanderson.org.